Incb28060
WebSynonyms: INC-280 2HCl, INCB28060 2HCl, INCB28060盐酸盐. INCB-28060 (free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-fold selectivity over a large panel of human kinases. WebSep 14, 2011 · Results. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. As a result, INCB28060 …
Incb28060
Did you know?
WebCapmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET … WebINCB28060, also known as Capmatinib and INC280, is a novel and ATP-competitive inhibitor of c-Met with IC50 of 0.13 nM. c-Met, also named as hepatocyte growth factor receptor …
WebMar 5, 2024 · INCB28060 (INC280) Treatment. I. Recruiting. Solid tumors NCT01324479 INCB28060 (INC280) Safety. I. Recruiting. Japanese Patients with Advanced Solid Tumors NCT01546428 INCB28060 (INC280) Safety/Efficacy. IB/II. Active, Not Recruiting. NSCLC, EGFR-mutated, c-MET-amplified, EGFR-inhibitor insensitive. Gefitinib. NCT01610336 … WebCapmatinib (INCB28060) is a potent, orally available selective inhibitor of the c-MET receptor tyrosine kinase, a clinically validated cancer target. Capmatinib (INCB28060) …
WebINCB28060, also known as Capmatinib and INC280, is a novel and ATP-competitive inhibitor of c-Met with IC50 of 0.13 nM. c-Met, also named as hepatocyte growth factor receptor … WebJul 15, 2024 · SECTION 1: Identification 1.1 GHS Product identifier Product name 2-fluoro-N-methyl-4- [7- (quinolin-6-ylmethyl)imidazo [1,2-b] [1,2,4]triazin-2-yl]benzamide 1.2 Other means of identification 1.3 Recommended use of the chemical and restrictions on use 1.4 Supplier's details 1.5 Emergency phone number SECTION 2: Hazard identification
WebINCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in Cancer treatment. Products Cat. No. Product Name Description Target …
WebMay 15, 2024 · Capmatinib (INC280, formerly INCB28060) is a highly selective and potent MET inhibitor with in vitro and in vivo activities against preclinical cancer models with MET activation . Capmatinib is being tested both as a single agent and in combination in multiple clinical trials that are guided by biomarker-based patient selection criteria. polyrecoveryWebCapmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor ( IC50 =0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream … shannon and wilson lake oswegoWebCapmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor INC280 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. shannon angel on facebookWebSep 16, 2024 · A high throughput apoptosis assay using 3D cultured cells was developed with a micropillar/microwell chip platform. Live cell apoptosis assays based on … shannon and wilson denvershannon angelottiWebCapmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1. poly rectangleWebINCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines shannon angelo